Cacicol®, a topical eye biopolymer containing a poly-carboxymethylglucose sulfate solution that is a regenerating matrix therapy agent, intended for wound healing of persistent corneal epithelial defects. Based on the chemical composition, we hypothesized that Cacicol® may compete with natural heparan sulfate (HS) which initiates cell surface attachment of herpes simplex virus type-1 (HSV-1), varicella zoster virus (VZV) and human adenovirus (HAdV), three viruses associated with corneal infections.
Methods
Cacicol® was compared to vehicle in the following viral strains: HSV-1 SC16 strain and HSV-1 PSLR, a clinical isolate highly resistant to acyclovir and foscarnet; VZV ATH and VZV FLO, two VZV clinical isolates; and HAdV-D37 strain. Viruses in Cacicol® or vehicle were added to cells for 1 h during adsorption then viral replication was assessed by plaque reduction assays on Vero cells for HSV-1 and MeWo cells for VZV and by immunostaining assay on Hep-2 cells for HAdV-D37.
Results
The vehicle had no effect, dose-dependent effects were demonstrated when HSV-1 SC16, HSV-1 PSLR, VZV ATH and VZV FLO were inoculated in the presence of Cacicol®, inhibiting viral replication by 98.4%, 98.9%, 90.1% and 89.0%, respectively. Cacicol® had no antiviral effect against HAdV-D37.
Conclusions
Cacicol® has a significant antiviral activity on HSV-1 and VZV, but not on HAdV-D37. The lack of effect on HAdV is probably because it is less dependent on HS interactions for cell entry. Clinical studies are necessary to determine Cacicol® for an adjunct or alternative therapy of corneal HSV-1 or VZV infection, particularly for the management of antiviral resistant HSV-1.
References
1.
KumarM., HillJ.M., ClementC., VarnellE.D., ThompsonH.W., KaufmanH.E.A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva.Invest Ophthalmol Vis Sci2009; 50: 5601–5608.
2.
LabetoulleM., AuquierP., ConradH.Incidence of herpes simplex virus keratitis in France.Ophthalmology2005; 112: 888–895.
3.
FarooqA.V., ShuklaD.Herpes simplex epithelial and stromal keratitis: an epidemiologic update.Surv Ophthalmol2012; 57: 448–462.
MadischI., HarsteG., PommerH., HeimA.Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy.J Virol2005; 79: 15265–15276.
8.
ZhouX., RobinsonC.M., RajaiyaJ.Analysis of human adenovirus type 19 associated with epidemic keratoconjunctivitis and its reclassification as adenovirus type 64.Invest Ophthalmol Vis Sci2012; 53: 2804–2811.
9.
IsmailA.M., LeeJ.S., DyerD.W., SetoD., RajaiyaJ., ChodoshJ.Selection pressure in the human adenovirus fiber knob drives cell specificity in epidemic keratoconjunctivitis.J Virol2016; 90: 9598–9607.
10.
DuanR., de VriesR.D., OsterhausA.D., RemeijerL., VerjansG.M.Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis.J Infect Dis2008; 198: 659–663.
11.
LiuJ., ThorpS.C.Cell surface heparan sulfate and its roles in assisting viral infections.Med Res Rev2002; 22: 1–25.
12.
TiwariV., ClementC., XuD.Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts.J Virol2006; 80: 8970–8980.
13.
BairdA., FlorkiewiczR.Z., MaherP.A., KanerR.J., HajjarD.P.Mediation of virion penetration into vascular cells by association of basic fibroblast growth factor with herpes simplex virus type 1.Nature1990; 348: 344–346.
14.
KanerR.J., BairdA., MansukhaniA.Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type 1.Science1990; 248: 1410–1413.
15.
ParkP.J., ShuklaD.Role of heparan sulfate in ocular diseases.Exp Eye Res2013; 110: 1–9.
16.
JacquetA., HaumontM., ChellunD.The varicella zoster virus glycoprotein B (gB) plays a role in virus binding to cell surface heparan sulfate proteoglycans.Virus Res1998; 53: 197–207.
17.
DechecchiM.C., TamaniniA., BonizzatoA., CabriniG.Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions.Virology2000; 268: 382–390.
18.
XeroudakiM., PeeboB., GermundssonJ., FagerholmP., LagaliN.RGTA in corneal wound healing after transepithelial laser ablation in a rabbit model: a randomized, blinded, placebo-controlled study.Acta Ophthalmol2016; 94: 685–691.
19.
Brignole-BaudouinF., WarnetJ.M., BarritaultD., BaudouinC.RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.J Fr Ophtalmol2013; 36: 740–747.
20.
CejkovaJ., OlmiereC., CejkaC., TrosanP., HolanV.The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage.Histol Histopathol2014; 29: 457–478.
21.
ChebbiC.K., KicheninK., AmarN.[Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].J Fr Ophtalmol2008; 31: 465–471. French.
22.
AifaA., GueudryJ., PortmannA., DelcampeA., MuraineM.Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.Invest Ophthalmol Vis Sci2012; 53: 8181–8185.
23.
De MonchyI., LabbeA., PogorzalekN.[Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): a case report].J Fr Ophtalmol2012; 35: 187e1-6. French.
24.
ThiT.N., DebackC., MaletI., BonnafousP., Ait-ArkoubZ., AgutH.Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR.Antiviral Res2006; 69: 152–157.
SchoonjansF., ZalataA., DepuydtC.E., ComhaireF.H.MedCalc: a new computer program for medical statistics.Comput Methods Programs Biomed1995; 48: 257–262.
27.
DuanR., de VriesR.D., van DunJ.M.Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis.J Infect Dis2009; 200: 1402–1414.
28.
van VelzenM., van de VijverD.A., van LoenenF.B., OsterhausA.D., RemeijerL., VerjansG.M.Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.J Infect Dis2013; 208: 1359–1365.
29.
GroahS.L., LibinA., SpungenM.Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study.Int Wound J2011; 8: 85–95.
30.
GruenheidS., GatzkeL., MeadowsH., TufaroF.Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans.J Virol1993; 67: 93–100.
31.
BanfieldB.W., LeducY., EsfordL., VisalliR.J., BrandtC.R., TufaroF.Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection.Virology1995; 208: 531–539.
32.
ShuklaN.D., TiwariV., Valyi-NagyT.Nectin-1-specific entry of herpes simplex virus 1 is sufficient for infection of the cornea and viral spread to the trigeminal ganglia.Mol Vis2012; 18: 2711–2716.
33.
ArvinA.M., OliverS., ReicheltM.Analysis of the functions of glycoproteins E and I and their promoters during VZV replication in vitro and in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis.Curr Top Microbiol Immunol2010; 342: 129–146.
34.
ChenJ.J., ZhuZ., GershonA.A., GershonM.D.Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster.Cell2004; 119: 915–926.
35.
SuenagaT., MatsumotoM., ArisawaF.Sialic acids on varicella-zoster virus glycoprotein B are required for cell-cell fusion.J Biol Chem2015; 290: 19833–19843.
36.
CohenJ.I., SeidelK.E.Absence of varicella-zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin.J Gen Virol1994; 75: 3087–3093.
37.
ImmergluckL.C., DomowiczM.S., SchwartzN.B., HeroldB.C.Viral and cellular requirements for entry of herpes simplex virus type 1 into primary neuronal cells.J Gen Virol1998; 79: 549–559.
38.
HadigalS.R., AgelidisA.M., KarasnehG.A.Heparanase is a host enzyme required for herpes simplex virus-1 release from cells.Nat Commun2015; 6: 6985.
39.
AgelidisA.M., HadigalS.R., JaishankarD., ShuklaD.Viral activation of heparanase drives pathogenesis of herpes simplex virus-1.Cell Reports2017; 20: 439–450.
40.
KimB., LeeS., KaisthaS.D., RouseB.T.Application of FGF-2 to modulate herpetic stromal keratitis.Curr Eye Res2006; 31: 1021–1028.
41.
TiwariV., LiuJ., Valyi-NagyT., ShuklaD.Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo.J Biol Chem2011; 286: 25406–25415.
ZaissA.K., FoleyE.M., LawrenceR.Hepatocyte heparan sulfate is required for adeno-associated virus 2 but dispensable for adenovirus 5 liver transduction in vivo.J Virol2015; 90: 412–420.
45.
RoweW.P., HuebnerR.J., GilmoreL.K., ParrottR.H., WardT.G.Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture.Proc Soc Exp Biol Med1953; 84: 570–573.
46.
WuE., TraugerS.A., PacheL.Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis.J Virol2004; 78: 3897–3905.
47.
MukherjeeS., ZhouX., RajaiyaJ., ChodoshJ.Ultrastructure of adenovirus keratitis.Invest Ophthalmol Vis Sci2015; 56: 472–477.
48.
DechecchiM.C., MelottiP., BonizzatoA., SantacatterinaM., ChilosiM., CabriniG.Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5.J Virol2001; 75: 8772–8780.
49.
TuveS., WangH., JacobsJ.D., YumulR.C., SmithD.F., LieberA.Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35.PLoS Pathog2008; 4: e1000189.
50.
NilssonE.C., StormR.J., BauerJ.The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis.Nat Med2011; 17: 105–109.
